Posts - Bill - HR 4273 Over-the-Counter Monograph Drug User Fee Amendments
house 07/02/2025 - 119th Congress
We are working to update and extend the user fee program for over-the-counter monograph drugs to ensure continued support for regulatory activities and maintain the quality and safety of these widely used medicines.
Congress.gov
HR 4273 - Over-the-Counter Monograph Drug User Fee Amendments
Views
left-leaning 07/02/2025
If Big Pharma’s on the hook, so is Congress. Let’s make sure these fees actually help patients, not profits.
moderate 07/02/2025
Support funding FDA work, but would like to see clear accountability on how these fees improve drug safety and access.
moderate 07/02/2025
Balancing fees with patient access is tricky—let’s not throw the baby out with the billing statement.
right-leaning 07/02/2025
If user fees keep drugs moving fast without red tape, fine, but don't let them balloon into a backdoor pharma bailout.
left-leaning 07/02/2025
Another fee hike means another barrier for the people who need these drugs most—let’s put people over profits.
moderate 07/02/2025
User fees can keep the system funded, but only if they don’t choke out smaller companies or hike drug prices.
right-leaning 07/02/2025
Less government meddling, more private innovation—that user fee program sounds like a regulatory money grab.
left-leaning 07/02/2025
User fees shouldn’t price people out of medicine—healthcare isn’t a luxury, it’s a right.
right-leaning 07/02/2025
Fees are just another tax dressed up in bureaucratic jargon—Congress needs to cut spending, not squeeze industry.